Are you Dr. Pereira?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 21 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Advanced Magnetics Inc.
125 Cambridge Park Drive, 6th Fl.
Cambridge, MA 02140Phone+1 617-498-3324- Is this information wrong?
Summary
- Dr. Brian Pereira, MD is an internist in Cambridge, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is an Adjunct Professor at Tufts Medical Center.
Education & Training
- Tufts Medical CenterFellowship, Nephrology, 1990 - 1993
- St. John's Medical CollegeClass of 1981
Certifications & Licensure
- MA State Medical License 1992 - 2012
Publications & Presentations
PubMed
- 33 citationsA Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathyJames R. Myette, Toshiki Kano, Hitoshi Suzuki, Susan Sloan, Kristy J. Szretter, Boopathy Ramakrishnan, Hedy Adari, Ketan D. Deotale, Frank Engler, Zachary Shriver, And...> ;Kidney International. 2019 Jul 1
- 99 citationsChallenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.Colin Baigent, William G. Herrington, Josef Coresh, Martin J Landray, Adeera Levin, Vlado Perkovic, Marc A. Pfeffer, Peter Rossing, Michael Walsh, Christoph Wanner, Da...> ;Kidney International. 2017 Aug 1
- 29 citationsBiosynthesis of poly(glycolate-co-lactate-co-3-hydroxybutyrate) from glucose by metabolically engineered Escherichia coli.Zheng-Jun Li, Kangjian Qiao, Weichao Shi, Brian Pereira, Haoran Zhang, Bradley D. Olsen, Gregory Stephanopoulos> ;Metabolic Engineering. 2016 May 1
- Join now to see all
Press Mentions
- Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent DirectorsJune 17th, 2020
- Rwandan Health Network Secures Funding for African ExpansionMarch 19th, 2019
- Analysts See $-0.51 EPS for KalVista Pharmaceuticals, Inc. (KALV)February 20th, 2019
- Join now to see all